Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ESMO 2022
Biotech
ESMO: Data boosts Regeneron's plans to 'take on' ovarian cancer
Regeneron is touting early phase 1 data of one of its bispecific antibodies aimed at treating ovarian cancer.
Max Bayer
Sep 12, 2022 10:10am
ESMO: Multi-cancer blood tests show promise but questions remain
Sep 12, 2022 9:43am
BioNTech's CAR-T response rate falls in updated early-phase data
Sep 12, 2022 8:58am
ESMO: Daiichi dazzles in lung cancer to dial up hopes for ADC
Sep 12, 2022 8:30am
Scoop: Dizal planning U.S. phase 3 NSCLC study in 2022
Sep 12, 2022 7:15am
ESMO: Relay spotlights expanded FGFR2 data
Sep 11, 2022 12:03pm
